Drug intelligence / Profile preview

HLX-0213

Development stage: Preclinical
Lead developer: Healx
Modality: Small Molecules
Administration: Oral

Overview

HLX-0213 is an investigational oral small molecule being developed by Healx for the treatment of Neurofibromatosis Type 1 (NF1). Identified through Healx's AI-supported research platform, the compound is designed to target cellular pathways associated with tumor growth in NF1. It is currently in preclinical development and represents a distinct program from Healx's more advanced candidate, HLX-1502. Specific molecular targets and the exact chemical structure have not been publicly disclosed.

Beyond the preview

Go deeper on HLX-0213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX-0213.

Explore the full profile